Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy JOURNAL OF NEUROLOGY Plazzi, G., Poli, F., Franceschini, C., Parmeggiani, A., Pirazzoli, P., Bernardi, F., Mignot, E., Cicognani, A., Montagna, P. 2008; 255 (10): 1549-1554

Abstract

We report on the outcome of intravenous high-dose immunoglobulin (IVIg) treatment in four children with narcolepsy and cataplexy, in whom the early diagnosis and the extreme disease severity were indications for this potentially efficacious therapy. One of four patients showed an objective and persistent improvement in clinical features during and after IVIg treatment. Our data partially support the recent report of the efficacy of IVIg treatment in early diagnosed narcolepsy with cataplexy and support the need for a controlled multicenter clinical trial on IVIg in narcolepsy.

View details for DOI 10.1007/s00415-008-0983-7

View details for Web of Science ID 000260877600016

View details for PubMedID 18769859